OREXIGEN THERAPEUTICS
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is ... a treatment for alcohol and opioid addiction. The company's Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.
OREXIGEN THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2002-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.orexigen.com
Total Employee:
101+
Status:
Active
Contact:
(858) 875-8600
Email Addresses:
[email protected]
Total Funding:
301 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Microsoft Exchange Online Amazon Office 365 Mail IPv6 Microsoft Azure DNS Microsoft Amazon Ohio Region
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
The Baupost Group
The Baupost Group investment in Post-IPO Equity - Orexigen Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Orexigen Therapeutics
Wasatch Advisors
Wasatch Advisors investment in Series C - Orexigen Therapeutics
MPM Capital
MPM Capital investment in Series C - Orexigen Therapeutics
Montreux Equity Partners
Montreux Equity Partners investment in Series B - Orexigen Therapeutics
Morgenthaler Ventures
Morgenthaler Ventures investment in Series B - Orexigen Therapeutics
Duke University
Duke University investment in Series B - Orexigen Therapeutics
Domain Associates
Domain Associates investment in Series B - Orexigen Therapeutics
Greenspring Associates
Greenspring Associates investment in Series B - Orexigen Therapeutics
Scale Venture Partners
Scale Venture Partners investment in Series B - Orexigen Therapeutics
Official Site Inspections
http://www.orexigen.com
- Host name: 209.17.116.163
- IP address: 209.17.116.163
- Location: Jacksonville United States
- Latitude: 30.1426
- Longitude: -81.5727
- Metro Code: 561
- Timezone: America/New_York
- Postal: 32258
